Wedbush analyst Robert Driscoll has maintained a Neutral rating on Replimune Group while raising the stock's price target to $9 from $6. The revised target reflects an updated valuation perspective on the biotechnology company, which is listed on NASDAQ under the ticker REPL.

The adjustment in the price target suggests a potential upside in the stock's current trading level, though the analyst remains cautious by retaining the Neutral stance. This rating indicates that the stock is expected to perform in line with the broader market or sector averages rather than significantly outperforming or underperforming in the near term.

Replimune Group focuses on the development of oncolytic immunotherapies, a sector that has seen varying investor interest based on clinical trial outcomes and regulatory progress. The new price target of $9 implies a specific valuation metric that Driscoll believes aligns more closely with the company's current fundamentals and future prospects.

Investors will likely monitor Replimune's upcoming clinical data releases and any regulatory updates that could influence the stock's performance relative to the new target. The maintenance of the Neutral rating suggests that while the outlook has improved, significant catalysts may be required to shift the sentiment to a more bullish rating.

Replimune Group reported a fiscal year 2026 net loss of $313.9 million, or $3.38 per share, compared to a net loss of $247.3 million, or $3.07 per share, in the prior year. For the fourth quarter, the company reported a loss of $0.76 per share, missing the analyst consensus estimate of $0.71 by 7.04%. This represents a 7.32% improvement over the loss of $0.82 per share reported in the same period last year. The U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma, setting a Prescription Drug User Fee Act (PDUFA) goal date of August 2, 2026.

The FDA classified the resubmission as a complete, class 1 response and indicated an advisory committee meeting is expected in late July. "The FDA’s acceptance of our RP1 BLA resubmission marks a pivotal milestone in our mission to bring this important therapy to patients facing advanced melanoma," said Sushil Patel, Ph.D., CEO of Replimune.

Financial Performance

Research and development expenses were $221.2 million for the fiscal year 2026, compared to $189.4 million in the prior year, driven by personnel-related costs for commercial launch scaling and consulting. Selling, general and administrative expenses were $98.7 million, up from $72.2 million in fiscal 2025.

As of March 31, 2026, cash, cash equivalents, and short-term investments were $268.9 million, a decrease from $483.8 million as of March 31, 2025. The company believes existing cash resources will fund operations into the first quarter of calendar 2027, excluding potential revenue.

Clinical and Regulatory Updates

The BLA submission is supported by data from the IGNYTE clinical trial. At the ASCO 2026 annual meeting, Replimune presented 3-year overall survival data showing 47.8% of treated patients were alive at 3 years, with a median overall survival of 32.9 months. The confirmatory IGNYTE-3 Phase 3 trial is actively enrolling.

For its RP2 program, the company reported final Phase 1 data showing a 19% objective response rate across multiple solid tumors. The registration-directed REVEAL Phase 2/3 trial in metastatic uveal melanoma is actively enrolling, with a Phase 2/3 transition expected in Q1 2027.